MX2017014436A - Compuestos biciclicos. - Google Patents

Compuestos biciclicos.

Info

Publication number
MX2017014436A
MX2017014436A MX2017014436A MX2017014436A MX2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A MX 2017014436 A MX2017014436 A MX 2017014436A
Authority
MX
Mexico
Prior art keywords
bicyclic compounds
compounds
ameliorating
nitrogen
treating
Prior art date
Application number
MX2017014436A
Other languages
English (en)
Inventor
Daniel Hopkins Chad
Helen Slee Deborah
Abraham Sunny
Robert Pinchman Joseph
Duane Bunker Kevin
Qinhua Huang Peter
Original Assignee
Kalyra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalyra Pharmaceuticals Inc filed Critical Kalyra Pharmaceuticals Inc
Publication of MX2017014436A publication Critical patent/MX2017014436A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Abstract

En la presente descripción se describen compuestos bicíclicos que contienen nitrógeno, junto con composiciones farmacéuticas y métodos para aliviar y/o tratar un cáncer descrito en la presente descripción con uno o más de los compuestos descritos en la presente descripción.
MX2017014436A 2015-05-12 2016-05-10 Compuestos biciclicos. MX2017014436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160413P 2015-05-12 2015-05-12
PCT/US2016/031663 WO2016183094A1 (en) 2015-05-12 2016-05-10 Bicyclic compounds

Publications (1)

Publication Number Publication Date
MX2017014436A true MX2017014436A (es) 2018-08-01

Family

ID=57249537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014436A MX2017014436A (es) 2015-05-12 2016-05-10 Compuestos biciclicos.

Country Status (14)

Country Link
US (1) US20180201614A1 (es)
EP (1) EP3294737A4 (es)
JP (1) JP2018515524A (es)
KR (1) KR20180003614A (es)
CN (1) CN107849036A (es)
AU (1) AU2016261730A1 (es)
BR (1) BR112017024163A2 (es)
CA (1) CA2984496A1 (es)
HK (1) HK1252614A1 (es)
IL (1) IL255357A0 (es)
MX (1) MX2017014436A (es)
RU (1) RU2017139771A (es)
TW (1) TW201706272A (es)
WO (1) WO2016183094A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
HUE056615T2 (hu) 2017-10-18 2022-02-28 Incyte Corp Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok
EP3921319B1 (en) * 2019-02-07 2024-03-06 BeiGene, Ltd. Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
WO2021016263A1 (en) * 2019-07-21 2021-01-28 University Of Virginia Patent Foundation Cysteine binding compositions and methods of use thereof
CN114081889A (zh) * 2020-12-29 2022-02-25 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587192A1 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
JP2011529073A (ja) * 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
KR20170013414A (ko) * 2008-12-08 2017-02-06 질레드 코네티컷 인코포레이티드 이미다조피라진 syk 억제제
TW201522332A (zh) * 2013-03-01 2015-06-16 Amgen Inc 經取代之7-酮基-吡啶并[2,3-d]嘧啶及其使用方法
UA115388C2 (uk) * 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
WO2016091916A1 (en) * 2014-12-10 2016-06-16 F. Hoffmann-La Roche Ag Pyrazolylaminopurines as itk inhibitors

Also Published As

Publication number Publication date
US20180201614A1 (en) 2018-07-19
HK1252614A1 (zh) 2019-05-31
WO2016183094A1 (en) 2016-11-17
RU2017139771A (ru) 2019-06-13
AU2016261730A1 (en) 2017-11-16
EP3294737A1 (en) 2018-03-21
CA2984496A1 (en) 2016-11-17
BR112017024163A2 (pt) 2018-07-17
TW201706272A (zh) 2017-02-16
IL255357A0 (en) 2017-12-31
EP3294737A4 (en) 2018-10-03
CN107849036A (zh) 2018-03-27
KR20180003614A (ko) 2018-01-09
JP2018515524A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
MX2019003938A (es) Compuestos espirociclicos.
MX2021007773A (es) Compuestos inhibidores de egfr.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2017001587A (es) Terapia de combinacion para tratar un paramixovirus.
MY187540A (en) Compounds active towards bromodomains
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2017012553A (es) Compuestos espirociclicos.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2017014436A (es) Compuestos biciclicos.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
JO3488B1 (ar) مثبط أرورا a كيناز
EP3413906A4 (en) COMBINATION COMPOSITIONS FOR CANCER TREATMENT, METHOD AND USES
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ZENO ROYALTIES & MILESTONES, LLC